Elizabeth Galvin

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.

Cooley advised AuditBoard, a leading connected risk platform transforming audit, risk, compliance, and environmental, social and governance (ESG) management, on its agreement to be acquired for more than $3 billion by Hg, an experienced and leading global investor in compliance, risk and accounting software over the last 20 years.

Cooley advised Jeito Capital, a leading global independent private equity fund dedicated to biopharma, on Biogen’s agreement to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments. Jeito began significantly investing in HI-Bio – a privately held, clinical-stage portfolio biotech company focused on targeted therapies for patients with severe immune-mediated diseases – in November 2022. Lawyers Courtney Thorne, Kate Hillier, Kevin Cooper, Ryan Montgomery, Sharon Connaughton and Elizabeth Galvin led the Cooley team advising Jeito.

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.

Cooley advised HealthTrio, a top provider of comprehensive health management and member engagement solutions, on its strategic acquisition by mPulse, which also announced its acquisition of Decision Point Healthcare Solutions.